{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:23Z","timestamp":1793398223798,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08580-6","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:54:32Z","timestamp":1783666472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibiotics"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei-Chi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Qi","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qing","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-176X","authenticated-orcid":false,"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"10183","key":"8580_CR1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7.","journal-title":"Lancet"},{"issue":"19","key":"8580_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-Cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"14","key":"8580_CR3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G, Esteban E, Felip E, D\u00f3mine M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-Cell lung cancer. JCO. 2020;38(14):1505\u201317. https:\/\/doi.org\/10.1200\/JCO.19.03136.","journal-title":"JCO"},{"issue":"11","key":"8580_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy in Squamous non\u2013small-Cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. JCO. 2023;41(11):1999\u20132006. https:\/\/doi.org\/10.1200\/JCO.22.01990.","journal-title":"JCO"},{"key":"8580_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lungcan.2019.01.017","volume":"130","author":"S Zhao","year":"2019","unstructured":"Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, et al. Antibiotics are associated with attenuated efficacy of anti-PD-1\/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019;130:10\u201317. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.017.","journal-title":"Lung Cancer"},{"issue":"10","key":"8580_CR6","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.21873\/anticanres.15312","volume":"41","author":"K Hamada","year":"2021","unstructured":"Hamada K, Yoshimura K, Hirasawa Y, et al. Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer patients on anti-PD-1 Immunotherapy. Anticancer Res. 2021;41(10):4985\u201393. https:\/\/doi.org\/10.21873\/anticanres.15312.","journal-title":"Anticancer Res"},{"issue":"1","key":"8580_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12885-022-09210-2","volume":"22","author":"AF Nyein","year":"2022","unstructured":"Nyein AF, Bari S, Hogue S, Zhao Y, Maller B, Sha S, et al. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer. 2022;22(1):101. https:\/\/doi.org\/10.1186\/s12885-022-09210-2.","journal-title":"BMC Cancer"},{"issue":"6","key":"8580_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437\u201344. https:\/\/doi.org\/10.1093\/annonc\/mdy103.","journal-title":"Ann Oncol"},{"issue":"1","key":"8580_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41698-024-00630-w","volume":"8","author":"A Elkrief","year":"2024","unstructured":"Elkrief A, M\u00e9ndez-Salazar EO, Maillou J, Vanderbilt CM, Gogia P, Desilets A, et al. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. npj Precis. Onc. 2024, Jul, 16;8(1):143. https:\/\/doi.org\/10.1038\/s41698-024-00630-w.","journal-title":"npj Precis. Onc"},{"issue":"7","key":"8580_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jtho.2020.03.002","volume":"15","author":"L Lurienne","year":"2020","unstructured":"Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, et al. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol. 2020, Jul;15(7):1147\u201359. https:\/\/doi.org\/10.1016\/j.jtho.2020.03.002.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"8580_CR11","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.21037\/tlcr-23-597","volume":"12","author":"A Abdelhamid","year":"2023","unstructured":"Abdelhamid A, Tuminello S, Ivic-Pavlicic T, Flores R, Taioli E. Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis. Transl Lung Cancer Res. 2023, Dec, 26;12(12):2427\u201339. https:\/\/doi.org\/10.21037\/tlcr-23-597.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"8580_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12967-024-05135-5","volume":"22","author":"WC Luo","year":"2024","unstructured":"Luo WC, Mei SQ, Huang ZJ, Chen Z-H, Zhang Y-C, Yang M-Y, et al. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer. J Transl Med. 2024, Apr, 2;22(1):326. https:\/\/doi.org\/10.1186\/s12967-024-05135-5.","journal-title":"J Transl Med"},{"issue":"2","key":"8580_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ijc.33557","volume":"149","author":"K Takada","year":"2021","unstructured":"Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, et al. Clinical impact of probiotics on the efficacy of anti-PD -1 monotherapy in patients with nonsmall cell lung cancer: a multicenter retrospective survival analysis study with inverse probability of treatment weighting. Intl J Cancer. 2021;149(2):473\u201382. https:\/\/doi.org\/10.1002\/ijc.33557.","journal-title":"Intl J Cancer"},{"key":"8580_CR14","doi-asserted-by":"publisher","unstructured":"Park U, Heo JY, Chun SM, Lee JC, Lee SH, Lee SW. Harnessing the gut microbiota to improve cancer immunotherapy: focus on lung cancer. Immune Netw. 2026, Feb, 19;26(1):e7. https:\/\/doi.org\/10.4110\/in.2026.26.e7.","DOI":"10.4110\/in.2026.26.e7"},{"issue":"6371","key":"8580_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science"},{"issue":"3","key":"8580_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41564-020-00831-6","volume":"6","author":"SH Lee","year":"2021","unstructured":"Lee SH, Cho SY, Yoon Y, Park C, Sohn J, Jeong J-J, et al. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat Microbiol. 2021;6(3):277\u201388. https:\/\/doi.org\/10.1038\/s41564-020-00831-6.","journal-title":"Nat Microbiol"},{"issue":"4","key":"8580_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022, Apr;28(4):704\u201312. https:\/\/doi.org\/10.1038\/s41591-022-01694-6.","journal-title":"Nat Med"},{"key":"8580_CR18","doi-asserted-by":"publisher","first-page":"140423","DOI":"10.1016\/j.scitotenv.2020.140423","volume":"741","author":"L Yang","year":"2020","unstructured":"Yang L, Hou K, Zhang B, Ouyang C, Lin A, Xu S, et al. Preservation of the fecal samples at ambient temperature for microbiota analysis with a cost-effective and reliable stabilizer EffcGut. Sci Total Environ. 2020;741:140423. https:\/\/doi.org\/10.1016\/j.scitotenv.2020.140423.","journal-title":"Sci Total Environ"},{"key":"8580_CR19","doi-asserted-by":"publisher","unstructured":"Fidelle M, Rauber C, Alves Costa Silva C, Tian A-L, Lahmar I, De La Varende A-LM, et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science. 2023;380(6649):eabo 2296. https:\/\/doi.org\/10.1126\/science.abo2296.","DOI":"10.1126\/science.abo2296"},{"issue":"10","key":"8580_CR20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-20-0051","volume":"8","author":"Y Tomita","year":"2020","unstructured":"Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol Res. 2020;8(10):1236\u201342. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0051.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"8580_CR21","doi-asserted-by":"publisher","first-page":"2186114","DOI":"10.1080\/19490976.2023.2186114","volume":"15","author":"H Xu","year":"2023","unstructured":"Xu H, Luo H, Zhang J, Li K, Lee MH. Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer. Gut Microbes. 2023, Jan-Dec;15(1):2186114. https:\/\/doi.org\/10.1080\/19490976.2023.2186114.","journal-title":"Gut Microbes"},{"issue":"6264","key":"8580_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy. Science. 2015;350(6264):1084\u201389. https:\/\/doi.org\/10.1126\/science.aac4255.","journal-title":"Science"},{"issue":"2","key":"8580_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1158\/1078-0432.CCR-25-1676","volume":"32","author":"R Garc\u00eda-Vicente","year":"2026","unstructured":"Garc\u00eda-Vicente R, Rodr\u00edguez-Garc\u00eda A, Ancos-Pintado R, Arroyo A, Ortega-Hern\u00e1ndez A, Bragado-Garc\u00eda I, et al. The potential of the gut microbiota and butyrate to enhance CAR T-cell therapy in Non-Hodgkin Lymphoma. Clin Cancer Res. 2026;32(2):375\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1676.","journal-title":"Clin Cancer Res"},{"key":"8580_CR24","doi-asserted-by":"publisher","first-page":"1791276","DOI":"10.3389\/fimmu.2026.1791276","volume":"17","author":"L Yang","year":"2026","unstructured":"Yang L, Li Z, Li Y, Zhang Q, Zhang H. Synergistic antitumor and immunomodulatory effects of Bifidobacterium animalis subsp. lactis V9 combined with anti\u2013PD-1 therapy. Front Immunol. 2026;17:1791276. https:\/\/doi.org\/10.3389\/fimmu.2026.1791276.","journal-title":"Front Immunol"},{"issue":"1","key":"8580_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-food-061120-014739","volume":"12","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Zhai Q, Zhang H, Chen W, Hill C. Gut colonization mechanisms of Lactobacillus and bifidobacterium: an argument for personalized designs. Annu Rev Food Sci Technol. 2021, Mar, 25;12(1):213\u201333. https:\/\/doi.org\/10.1146\/annurev-food-061120-014739.","journal-title":"Annu Rev Food Sci Technol"},{"issue":"6","key":"8580_CR26","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1073\/pnas.1115621109","volume":"109","author":"S Fanning","year":"2012","unstructured":"Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D, et al. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci USA. 2012;109(6):2108\u201313. https:\/\/doi.org\/10.1073\/pnas.1115621109.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"8580_CR27","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3390\/microorganisms9081573","volume":"9","author":"X Luo","year":"2021","unstructured":"Luo X, Kong Q, Wang Y, Duan X, Wang P, Li C, et al. Colonization of Clostridium butyricum in rats and its effect on intestinal microbial composition. Microorganisms. 2021;9(8):1573. https:\/\/doi.org\/10.3390\/microorganisms9081573.","journal-title":"Microorganisms"},{"key":"8580_CR28","doi-asserted-by":"publisher","first-page":"106302","DOI":"10.1016\/j.mimet.2021.106302","volume":"189","author":"MA Lopez-Pier","year":"2021","unstructured":"Lopez-Pier MA, Koppinger MP, Harris PR, Cannon DK, Skaria RS, Hurwitz BL, et al. An adaptable and non-invasive method for tracking Bifidobacterium animalis subspecies lactis 420 in the mouse gut. J Microbiological Methods. 2021;189:106302. https:\/\/doi.org\/10.1016\/j.mimet.2021.106302.","journal-title":"J Microbiological Methods"},{"issue":"4","key":"8580_CR29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41591-025-04186-5","volume":"32","author":"S Duttagupta","year":"2026","unstructured":"Duttagupta S, Messaoudene M, Hunter S, Desilets A, Jamal R, Mihalcioiu C, et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat Med. 2026;32(4):1337\u201350. https:\/\/doi.org\/10.1038\/s41591-025-04186-5.","journal-title":"Nat Med"},{"key":"8580_CR30","doi-asserted-by":"publisher","first-page":"104533","DOI":"10.1016\/j.ebiom.2023.104533","volume":"91","author":"G Gao","year":"2023","unstructured":"Gao G, Shen S, Zhang T, Zhang J, Huang S, Sun Z, et al. Lacticaseibacillus rhamnosus probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine. 2023;91:104533. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104533.","journal-title":"EBioMedicine"},{"issue":"8","key":"8580_CR31","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, et al. The diversity of gut microbiome is associated with favorable responses to anti\u2013programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019;14(8):1378\u201389. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.007.","journal-title":"J Thorac Oncol"},{"issue":"6371","key":"8580_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, et al. The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104\u201308. https:\/\/doi.org\/10.1126\/science.aao3290.","journal-title":"Science"},{"issue":"11","key":"8580_CR33","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1136\/gutjnl-2023-330291","volume":"72","author":"X Kang","year":"2023","unstructured":"Kang X, Liu C, Ding Y, Ni Y, Ji F, Lau HCH, et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells. Gut. 2023;72(11):2112\u201322. https:\/\/doi.org\/10.1136\/gutjnl-2023-330291.","journal-title":"Gut"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08580-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08580-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08580-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:32:16Z","timestamp":1786354336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08580-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8580"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08580-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee at Guangdong Provincial People\u2019s Hospital, No. GDREC2016175H (R2). All patients were informed of the study and consented to the enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Y.L Wu reports grants and personal fees from AstraZeneca, BMS, Pfizer; and personal fees from Boehringer Ingelheim, Eli Lilly, Hengrui, MSD, Sanofi, Roche, outside the submitted work. The other authors have no competing interests to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1022"}}